<bill session="118" type="h" number="4134" updated="2024-07-26T08:05:38Z">
  <state datetime="2023-06-14">REFERRED</state>
  <status>
    <introduced datetime="2023-06-14"/>
  </status>
  <introduced datetime="2023-06-14"/>
  <titles>
    <title type="display">Updated Drug Labeling for Patient Safety Act</title>
    <title type="short" as="introduced">Updated Drug Labeling for Patient Safety Act</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to establish a process to allow the holders of abbreviated new drug applications to make labeling changes to include new or updated safety-related information, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="S001150"/>
  <cosponsors>
    <cosponsor bioguide_id="B001300" joined="2023-06-15"/>
    <cosponsor bioguide_id="K000382" joined="2023-06-14"/>
    <cosponsor bioguide_id="T000469" joined="2024-07-25"/>
  </cosponsors>
  <actions>
    <action datetime="2023-06-14">
      <text>Introduced in House</text>
    </action>
    <action datetime="2023-06-14" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2023-06-16">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2023-10-18T17:46:38Z" status="Introduced in House">Updated Drug Labeling for Patient Safety Act

This bill allows generic drug manufacturers to revise labels with updated safety information that differs from the referenced brand-name drug.</summary>
</bill>
